5002592026-04-012026-06-305002592026-04-012026-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares500259LYKALABSNOTLISTEDINE933A01014LYKA LABS LIMITEDMain BoardEquity2026-04-012027-03-312026-08-102026-07-24INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-08-1011:00:002026-08-1012:20:00Not applicablefalsefalseNot applicable2026-04-012026-06-30UnauditedStandalone423094000418500042727900011204100075015000-22572000114761000100820002009600097921000407344000199350000199350000-1068000-1068000021003000000021003000021003000361527000100.580.58000.580.581.The above Unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 10th August 2026. <br /> <br /> 2.The Hon’ble National Company Law Tribunal (‘NCLT’), Ahmedabad Bench, has sanctioned the Scheme of Amalgamation for the merger of Lyka Export Limited (the Transferor Company), with the Lyka Labs Limited (the Transferee Company), under Sections 230 to 232 of the Companies Act, 2013, vide its Order dated 16th March 2026. <br /> The accounting treatment pursuant to the scheme has been given effect to from the date required under IND AS 103 – Business Combinations, which is the beginning of the preceding period presented i.e. April 1, 2024. Accordingly, the figures has been restated for respective periods. <br /> <br /> 3.The Statutory Auditors have expressed an unqualified Conculsion on the Unaudited Standalone financials results for the quarter 30th June 2026. <br /> <br /> 4.The Company operates in one business segment i.e. “Pharmaceuticals”. <br /> <br /> 5.The figures for the previous year have been restated / rearranged wherever considered necessary. <br /> <br /> <br /> <br /> Other expenses97921000